Samsung invests in BrickBio in US

Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technologies company BrickBio.

The Samsung Life Science Fund is a venture investment fund jointly formed by Samsung C&T Corp., Samsung Biologics Co., and Samsung Bioepis in 2021.

This is the fifth investment of the fund.

According to Samsung, the size of the deal is undisclosed because it's an investment and not an acquisition of control.

Antibody-drug conjugates (ADCs) are emerging as next-generation anticancer drugs that have attracted global attention.

Samsung plans to explore new bio business opportunities such as ADCs and adeno-associated viruses (AAVs) using BrickBio's proprietary artificial amino acid-based conjugation technology.

Write to Dae-Kyu Ahn at powerzani@hankyung.com